NCT03267862 is a clinical trial of there was no intervention in Glaucoma, Open-Angle, sponsored by Johns Hopkins University.

Who is sponsoring NCT03267862?

NCT03267862 is sponsored by Johns Hopkins University.

What drugs are being tested in NCT03267862?

Interventions in NCT03267862: there was no intervention.

What condition does NCT03267862 study?

NCT03267862 studies Glaucoma, Open-Angle.

Is NCT03267862 still recruiting?

NCT03267862 is currently completed. Last updated 30 August 2017.

Last reviewed 2017-08-30 · How we verify

NCT03267862

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Scleral Response to Intraocular Pressure (IOP)

Completed Last updated 30 August 2017

What this trial tests

trial testing there was no intervention in Glaucoma, Open-Angle in 27 participants. Completed in 29 August 2017.

Timeline

17 September 2014

Primary endpoint
29 August 2017

29 August 2017

Quick facts

Lead sponsor	Johns Hopkins University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	27
Start date	17 September 2014
Primary completion	29 August 2017
Estimated completion	29 August 2017

Drugs / interventions tested

there was no intervention

Conditions studied

Glaucoma, Open-Angle — all drugs for Glaucoma, Open-Angle →

Sponsor

Johns Hopkins University

Who can join

Adults 21 to 100, any sex, with Glaucoma, Open-Angle. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study evaluated changes in the depth of the lamina cribrosa at different eye pressures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Glaucoma, Open-Angle

Currently open trials in the same condition.

NCT06964191 — Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension · Phase 2 · recruiting
NCT06240312 — Optic Nerve Head Strain as Biomarker for Glaucoma · NA · recruiting
NCT05405868 — Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial · Phase 3 · recruiting
NCT05710198 — Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma · Phase 3 · recruiting
NCT06058598 — Exercise Training in Patients With Glaucoma · NA · active not recruiting

Other Johns Hopkins University trials

Trials by the same sponsor.

NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03267862 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 30 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03267862.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing